Emerging Therapy Retatrutide Retatrutide is a new emerging (LY-3437943) is a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors currently under trial conducted by Eli Lilly and Company Mechanism of Action GIP agonism enhances insulin release, suppresses appetite, inhibits fat accumulation GLP-1 agonism enhances insulin release, suppresses glucagon, slows gastric emptying Glucagon receptor agonism boosts energy expenditure, supports glycemic control Collectively, it addresses glucose homeostasis, appetite regulation, energy metabolism, and weight loss Competitive Edge over Existing Therapies Superior efficacy: Around 24% weight loss surpasses GLP-1-only treatments (e.g., semaglutide, tirzepatide)
Gastric bypass and banding equally improve insulin sensitivity and beta cell function
Because they are FDA-approved for type II diabetes many physicians may not be aware of how helpful they can be, which means its up to you to look into them and be your own advocate
Beyond these concerns, theres now a family ranging from single to triple G-agonists and we have no idea how such potent interventions should be optimally used
The simplest way to think about it: semaglutide reduces input
B12 Injections Is your slow metabolism a problem
.webp)
)
